Repurposing Domperidone in Secondary Progressive Multiple Sclerosis: A Simon 2-Stage Phase 2 Futility Trial.

Marcus Werner KochKayla SageSharanjit KaurJanet KimGraziela CerchiaroV Wee YongGary R CutterLuanne M Metz

Published in: Neurology (2021)

This study provides Class III evidence that in individuals with SPMS participating in a futility trial, domperidone treatment could not reject futility in reducing disability progression at 12 months.

Keyphrases

multiple sclerosis
phase iii
study protocol
phase ii
clinical trial
white matter
randomized controlled trial
open label
combination therapy